Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Merck, Cue Biopharma Set Strategic Research Collaboration and License Agreement

By Cue Biopharma | November 20, 2017

Cue Biopharma, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, announced a strategic research collaboration and license agreement with Merck, known as MSD outside of the United States and Canada. Under the terms of the deal, the CUE Biologics™ platform will be leveraged to develop biologics engineered to selectively modulate disease-relevant T cell subsets for the treatment of autoimmune disease. The multi-year collaboration will encompass multiple disease targets across certain primary disease indication areas.

While specific financial arrangements are not being disclosed, Cue Biopharma will receive an up-front payment. Cue Biopharma is also eligible to earn up to $374 million in research, development, regulatory and commercial milestone payments in addition to tiered royalties on sales, if all pre-specified milestones associated with multiple products across the primary disease indication areas are achieved.

Immune Responses, On Cue™

Cue Biopharma is developing biologics that mimic antigen presenting cells (APCs) to selectively and effectively deliver signals to disease-associated T cells. This approach to generating highly targeted and selective T cell responses could result in more effective and safer therapies for addressing cancer and autoimmune diseases. We have developed a proprietary platform for the design and development of CUE Biologics for in vivo (in the patient’s body) T cell-based immunotherapy. In the context of cancer, CUE Biologics are designed to selectively activate disease-associated T cells to proliferate and attack tumor cells. For the treatment of autoimmune diseases, CUE Biologics are designed to selectively ablate disease-associated T cell responses directed against self tissue.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE